|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 358.33 USD | +1.56% |
|
+6.14% | +9.48% |
| Jun. 26 | US FDA greenlights Viridian's thyroid eye disease drug | RE |
| Jun. 26 | US FDA greenlights Viridian's eye disease drug | RE |
| Market Cap | 193B 170B 156B 146B 274B 18,243B 280B 1,879B 727B 9,016B 726B 710B 31,264B | P/E 2026 * |
23.3x | P/E 2027 * | 21.2x |
|---|---|---|---|---|---|
| Enterprise Value | 235B 206B 190B 178B 333B 22,133B 340B 2,279B 882B 10,939B 881B 862B 37,930B | EV / Sales 2026 * |
6.21x | EV / Sales 2027 * | 5.9x |
| Free-Float |
99.78% | Yield 2026 * |
2.81% | Yield 2027 * | 2.97% |
Last Transcript: Amgen Inc.
| 1 day | +1.56% | ||
| 1 week | +6.14% | ||
| Current month | +6.40% | ||
| 1 month | +6.63% | ||
| 3 months | +2.74% | ||
| 6 months | +7.63% | ||
| Current year | +9.48% |
| 1 week | 337.6 |  | 362.27 |
| 1 month | 322.3 | | 362.27 |
| Current year | 318.21 | | 391.29 |
| 1 year | 269.77 | | 391.29 |
| 3 years | 218.44 | | 391.29 |
| 5 years | 198.64 | | 391.29 |
| 10 years | 133.64 | | 391.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 2019-12-31 |
Esteban Santos
COO | Chief Operating Officer | 59 | 2016-07-24 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% | ||
| May. 18 | Free | Director | 665 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.56% | +6.14% | +29.30% | +60.97% | 193B | |
| +7.13% | +9.97% | +55.80% | +160.09% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +55.96% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.06% | 448B | |
| +0.99% | +4.85% | +28.17% | +23.89% | 332B | |
| +1.82% | +8.19% | +40.04% | +27.95% | 293B | |
| +0.22% | +6.75% | +31.30% | +42.34% | 286B | |
| +0.73% | +8.53% | -27.33% | -39.55% | 215B | |
| +3.26% | +3.33% | +15.55% | +68.24% | 159B | |
| +2.62% | -3.65% | +0.41% | -33.31% | 138B | |
| Average | +2.65% | +6.59% | +27.93% | +45.76% | 375.45B | |
| Weighted average by Cap. | +3.80% | +8.37% | +40.23% | +75.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 37.78B 33.13B 30.53B 28.59B 53.6B 3,564B 54.72B 367B 142B 1,761B 142B 139B 6,108B | 38.75B 33.97B 31.32B 29.32B 54.98B 3,655B 56.12B 376B 146B 1,807B 146B 142B 6,264B |
| Net income | 8.26B 7.25B 6.68B 6.25B 11.73B 780B 11.97B 80.28B 31.07B 385B 31.03B 30.36B 1,336B | 9.04B 7.93B 7.31B 6.84B 12.83B 853B 13.09B 87.82B 33.98B 421B 33.95B 33.21B 1,462B |
| Net Debt | 41.23B 36.15B 33.32B 31.2B 58.5B 3,889B 59.72B 401B 155B 1,922B 155B 151B 6,666B | 35.08B 30.76B 28.35B 26.55B 49.78B 3,309B 50.81B 341B 132B 1,636B 132B 129B 5,672B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-26 | $358.33 | +1.56% | 3,610,561 |
| 26-06-25 | $352.82 | +0.40% | 2,341,847 |
| 26-06-24 | $351.43 | +1.27% | 2,391,890 |
| 26-06-23 | $347.01 | +0.66% | 2,304,951 |
| 26-06-22 | $344.72 | +2.11% | 2,520,964 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
